Dragon Pharmaceutical Inc.
OTC Bulletin Board : DRUG
TSX : DDD

Dragon Pharmaceutical Inc.

August 15, 2005 13:24 ET

Dragon Announces Results of the Annual General Meeting

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 15, 2005) - Dragon Pharmaceutical Inc. (TSX:DDD)(OTCBB:DRUG) ("the Company") is pleased to announce the results of the Annual Shareholders' Meeting held on August 12, 2005.

There were 54,818,706 shares equaling 87.20% of the outstanding shares represented at this meeting. All of the following proposals were approved by a substantial majority of votes:

- Election of Mr. Yanlin Han, Dr. Alexander Wick, Ms Xuemei Liu, Mr. Zhanguo Weng, and Dr. Yiu Kwong Sun as the directors;

- Amendment to Certificate of Incorporation to eliminate Article VII which states a specified number of directors;

- Amendment to the By-laws of the Company to allow the Board of Directors to set the number of directors at a range from 1 to 11;

- Adoption of 2005 Stock Option Plan.

"We are very pleased to see the support of our shareholders on all proposals," said by Yanlin Han, Chairman and CEO of the Company, "The amendments to our by-laws and Certificate of Incorporation will allow us to expand our board and appoint additional directors. We intend to appoint additional independent board members to meet the American Stock Exchange (AMEX) listing standard, which requires a majority of the Board to be independent directors. In addition, we intend to establish an audit committee and a compensation committee consisting of solely independent directors. The Company is in the final stage of searching for appropriate individuals as the independent Board members who will bring along their valuable experience and creditability for the Company to move forward."

About Dragon Pharmaceutical Inc.

Incorporated in Florida, USA, Dragon Pharmaceutical Inc. is an international pharmaceutical company headquartered in Vancouver, Canada, with three key business units consisting of a Pharma division for 52 generic prescription, over-the-counter and sterilized bulk drugs; a Chemical division for bulk pharmaceutical chemicals and intermediates (Clavulanic Acid and 7-ACA); and a Biotech division for recombinant drugs (EPO and G-CSF). The Company has four manufacturing facilities in China (three in Datong city and one in Nanjing city), approximately 1,800 employees, plus over 1,200 sales representatives in China, and approximately 58 key products in 90 different dosages and presentations currently in market.

This press release contains forward looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward looking statement. Readers should not place undue reliance on forward looking statements, which only reflect the view of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward looking statements to reflect subsequent events or circumstances. Readers should carefully review the risk factors and other factors described in its periodic reports with the Securities and Exchange Commission.


Contact Information